Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model

Hans D. Menssen,Ulf Harnack,Ulrike Erben,Dario Neri,Burkhard Hirsch,Horst Dürkop

Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model

2018

Hans D. Menssen
Ulf Harnack
Ulrike Erben
Dario Neri
Burkhard Hirsch
Horst Dürkop

Purpose To analyze the impact of TNFα or IL2 on human lymphocytes in vitro and the anti-tumor and immune-modifying effects of L19-IL2 and L19-TNFα on subcutaneously growing J558L myeloma in immunocompetent mice.

Keywords:

Antibody
Immunology
Tumor necrosis factor alpha
PD-L1
Interleukin 2
BALB/c
Biology
Immunotherapy
T cell
Peripheral blood mononuclear cell
Necrosis
Cancer research
Immune system

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations